Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$XXII - great read from Jason Napodono at Bionap
http://www.bionapcfa.com/2016/01/22nd-century-group-filed-modified-risk.html
$XXII 22nd Century Files Modified Risk Tobacco Product Application with the FDA for World’s Lowest Nicotine Tobacco Cigarettes
http://finance.yahoo.com/news/22nd-century-files-modified-risk-145000347.html
$GGG.V Nice mention of Graphene 3D Lab
Beyond Makerbot: How New York’s 3D printing industry awkwardly matured in 2015
http://www.bizjournals.com/newyork/news/2015/12/31/beyond-makerbot-how-new-york-s-3d-printing.html?ana=twt
Nice- thanks!
From "Let Your Biotech Winners Ride into Orbit: Jason Napodano of BioNap"
JN: Actinium Pharmaceuticals Inc. (ATNM:OTCQB) has a platform for acute myeloid leukemia (AML). It has two drugs, one of which is called Iomab-B, a conditioning regimen for really sick patients who may not be able to withstand standard conditioning for bone marrow transplant. The other drug, Actimab-A, is earlier stage, and is for elderly patients with AML who cannot tolerate standard of care.
Iomab-B, a radioactive iodine on a targeted monoclonal antibody, is in Phase 3, and it's like SEAL Team 6. It's a very interesting approach that delivers radiation to the bone marrow cells in a more targeted way to obliterate it without too much toxicity to the rest of the body, to avoid treatment-related mortality.
Standard conditioning often includes some combination of total body irradiation and chemotherapy, and is designed to knock out all of the bone marrow ahead of a hematopoietic stem cell bone marrow transplant. If you have AML, you are producing cancerous blast cells that are not maturing to full white blood cells. The goal is to wipe out the bone marrow, which wipes out all the cancerous cells. With a transplant of healthy marrow from a matched donor, you could potentially cure the AML. In fact, AML is a curable cancer if the treatment option works.
However, standard conditioning is difficult to tolerate if you are elderly or you have comorbidities. It's a balancing act between enough radiation and enough chemotherapy to kill the bone marrow and prevent post-transplant graft rejection, but not so powerful that the patient dies.
TLSR: To be fair, a lot of small-cap biotechs are down from a year ago, but the market doesn't seem to have appreciated Actinium. With a $76M market cap it is large enough for some small-cap institutions to own, but it hasn't gotten Wall Street's attention. Is there an issue you can pinpoint?
JN: Actinium isn't the first company to develop a targeted monoclonal antibody with radioisotopes attached. There have been other drugs, and there have also been a lot of failures in the AML space. Pfizer Inc. (PFE:NYSE) had a drug that came with its Wyeth acquisition called Mylotarg (gemtuzumab ozogamicin), but it was pulled from the market. Bexxar (tositumomab + iodine I 131 tositumomab/ GlaxoSmithKline [GSK:NYSE]) was on the market and just didn't sell, so GSK discontinued it. Zevalin (ibritumomab tiuxetan) from Spectrum Pharmaceuticals Inc. (SPPI:NASDAQ) is still on the market but doesn't do very well. Each of these drugs has specific issues: They are too toxic, or they are too difficult to prepare, or they don't have centralized manufacturing.
Actinium's drug, and specifically Actimab, which is going to be a first-line therapy for elderly patients with AML, has certain advantages over these failed drugs. The market just hasn't caught on yet. It's possible the market is not giving Actinium enough credit for the changes it has made and the improvements in strategy. That would be a guess.
I really like Actinium's platform. I think radiolabeled immunotherapies have a place in the future treatment of hematological cancers. Everyone is excited about the chimeric antigen receptor (CAR) T cells being developed for leukemias and lymphomas by companies like Juno Therapeutics (JUNO:NASDAQ), Kite Pharma (KITE:NASDAQ) and bluebird bio Inc. (BLUE:NASDAQ), and these companies have market caps that are tenfold Actinium's just because of that excitement. But I think an effective, radiolabeled, targeted monoclonal antibody will be met with enthusiastic response by the oncologist community, as long as it has improvements and advantages over the older drugs. I think Actinium has the right strategy.
http://www.thelifesciencesreport.com/pub/na/let-your-biotech-winners-ride-into-orbit-jason-napodano-of-bionap-consulting
$ATNM Dr. Phillip Frost likes it
http://finance.yahoo.com/news/actinium-announces-5-million-registered-183525790.html
$VUZI is one of "7 Small Cap Stocks set to Bounce in 2016"
My article @ http://microcapresearch.com/best-microcap-stocks-2016/
I've been long for a year now (since day of Intel investment) and looking forward to a breakout year.
Good CES buzz coming in 2 weeks!
Happy Holidays all
$GLUU is one of "7 Small-Cap Stocks set to Bounce in 2016"
Article @ 7 Small-Cap Stocks set to Bounce in 2016
$XXII: Why You Should Get To Know 22nd Century Group
http://www.bionapcfa.com/2015/12/why-you-should-get-to-know-22nd-century.html
yep- I wish they were all like this- but it takes more time for some to catch on with investors than others.
I think the climate change talks in Paris are helping here.
$MNGA breaks $2. Congrats all
That's a 125% gain from our September article: http://microcapresearch.com/magnegas/
And yes, I still own the stock, and it will be $5+ in 2016, based on fundamental growth IMO.
(Subscription to our service is free incidentally, @ http://microcapresearch.com/subscribe-to-microcapresearch/ )
Great read- "3D Printing Will Rock the World"
#1 bestseller in 3D printing books.
http://www.amazon.com/3D-Printing-Will-Rock-World/dp/1516946790/ref=sr_1_1?ie=UTF8&qid=1449616171&sr=8-1&keywords=3D+printing+John+Hornick
http://www.amazon.com/3D-Printing-Will-Rock-World/dp/1516946790/ref=sr_1_1?ie=UTF8&qid=1449616171&sr=8-1&keywords=3D+printing+John+Hornick
I have a Davinci 2.0
http://us.xyzprinting.com/us_en/Product/da-Vinci-2.0?gclid=Cj0KEQiAnJqzBRCW0rGWnKnckOIBEiQA6qDBapD0dTHexDy_wuQOFWMNRUmCrqtM4qnQeu6MOQ4SRLoaAs7L8P8HAQ
Company is XYZ printing, a subsidiary of a large company in New Kinpo Group in Taiwan.
Only 3 stars on Amazon- I give it 4 personally. Some issues with plate auto level function at first.
Amazon link: http://www.amazon.com/XYZprinting-Vinci-2-0-Printer-Blue/dp/B00T472HII/ref=sr_1_1?ie=UTF8&qid=1449615873&sr=8-1&keywords=davinci+2.0
And they're closer to launching the multimaterial 3D printer than I thought
Our main focus is developing specialized 3D printing techniques and materials that push past the boundaries of what is currently available."
The printer will not be available immediately for pre-order. The company is currently evaluating contract manufacturing and partnership opportunities to support commercialization of the printer
http://finance.yahoo.com/news/graphene-3d-lab-files-patent-134000002.html
$GGG.V Graphene 3D Lab Files Patent Application for Industry's Most Advanced 3D Printer And Innovative, Graphene Based Organic LED Light Source
http://finance.yahoo.com/news/graphene-3d-lab-files-patent-134000002.html
Hi Boris
LOL
So impatient.
~ Patents usually take years to go thru the system, not weeks/months.
~Merger with Graphehe Lab should be complete by eoy (see yesterday's pr). That should give them pretty strong cash flow- over $1M in revenue annually. My understand is that Graphene Lab was/is cash flow positive.
~Sales of multimaterial printers was never estimated to start by this time. The original and continuing timeline is for sales to begin sometime between Q1 of 2016 year and Q1 of 2017.
~And the nice part about the agreement from yesterday is the Fortune 500 company is paying for R&D while GGG will share revenues from product launch (assuming there is one) and retain intellectual property with Fortune 500 company.
Well, it's not the address actually.
I've been there. I've met the co-CEOs as well as the financial backers of the company.
And the deal announced yesterday indicates GGG has something attractive to a large player.
$GPHBF - Very nice news today & record volume
http://finance.yahoo.com/news/graphene-3d-lab-announces-r-130000753.html
$GGG.V/ Graphene 3D Lab Announces Agreement with Fortune 500 Company
http://finance.yahoo.com/news/graphene-3d-lab-announces-r-130000087.html
All the low floaters are flying. ATNM should do a 1:25 reverse... Stock would triple on that news alone.
Crazy cheap here and I added on today's news.
As you point out, there hasn't been much that's positive in the 3D printing space... at least in the publicly-traded companies.
The 3D printing and technology fund was being liquidated last week- and that probably caused much (if not most?) of the selling pressure on GGG.
End of year tax selling won't help much- so I might be looking to add if there's more weakness. I remain positive about the longer term and their expanding patents, first mover advantage, and more.
$ATNM Actinium Files Orphan Drug Application for Use of Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients
http://finance.yahoo.com/news/actinium-files-orphan-drug-application-130000725.html
$ATNM: Actinium Submits Iomab-B IND Application to the U.S. FDA
http://finance.yahoo.com/news/actinium-submits-iomab-b-ind-230000851.html
yep- Jason is a great resource for finding undiscovered biotech and pharma stocks.
One of his articles got me into NVIV back in December, about 500% ago.
$ATNM: Actinium Pharmaceuticals: An Impressive Platform Targeting Leukemia
Jason Naopdano
http://www.bionapcfa.com/2015/11/actinium-pharmaceuticals-platform.html
$ATNM: Good read by Jason Napodano on this one
http://www.bionapcfa.com/2015/11/actinium-pharmaceuticals-platform.html
yep. Would love for them to announce something soon with Sysmex.
Just a waiting game.
Yes, I own Arcam- best tech. out there for aerospace IMO.
Not sure if you like penny stocks or not- but TTD.V/ TKSTF has some impressive growth also. Here's the pr with Video of CFO.
http://finance.yahoo.com/news/tinkerine-reports-q3-2015-financial-110000474.html
They expect to be cash flow + by Q4.
$DDD Buying (small position) back in $8s
Could easily go lower though- shorts very active in it again.
So only taking starter here
$AMDA Amedica Submits 24-Month Clinical Data to FDA for Clearance of Composite Interbody Spinal Device
currently .25x.27 in PM
http://finance.yahoo.com/news/amedica-submits-24-month-clinical-211500497.html
$SPSH getting jiggly
Could busta move for close?
You might be right about that
$SPHS Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint
http://finance.yahoo.com/news/sophiris-bio-phase-3-bph-131800386.html
Phase 3 trial of BPH drug - and market cap $42M?????
Looks like a lot of $VRX shorts covering to open new MNK positions
Sudden spike started in VRX at same time.
Prior Q read:
"In addition, if Sysmex determines the Study to be successful, during the term of the Agreement, both parties will determine the terms under which Bio-AMD Ltd. will either manufacture the Products or license its intellectual property to allow the third-party manufacture of the Products, and for the terms under which Sysmex acquires the manufactured Products and its commercial resale.
There can be no assurance that the Study will be successfully completed or that Sysmex will enter into additional agreements to jointly develop with us the Products or that such a manufacturing/license agreement will ever be consummated or that the Products will ever be commercially sold by Sysmex."
So, this part is new.
"We expect the study to be completed in line with expectations."
I'm on bid now if anyone is disappointed/wants to sell.
Sysmex deal announcement could come any day now- or it may not ever.
But I'm still betting it happens and this goes to $1+
$EDAP- out small loss.
Don't have time or money to waste on biotech weakness.